Fmr LLC Buys 100,345 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

FMR LLC lifted its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 2,676.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 104,094 shares of the medical instruments supplier's stock after acquiring an additional 100,345 shares during the quarter. FMR LLC owned 0.43% of ICU Medical worth $18,968,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the business. Innealta Capital LLC acquired a new stake in ICU Medical in the 2nd quarter worth about $32,000. Hexagon Capital Partners LLC boosted its position in shares of ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier's stock worth $36,000 after buying an additional 122 shares during the period. Allworth Financial LP boosted its position in ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 100 shares during the period. Venturi Wealth Management LLC lifted its stake in ICU Medical by 1,510.0% in the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier's stock worth $59,000 after acquiring an additional 302 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of ICU Medical in the 2nd quarter valued at $70,000. Institutional investors own 96.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ICUI. Raymond James increased their price objective on ICU Medical from $158.00 to $190.00 and gave the company an "outperform" rating in a report on Thursday, September 12th. Jefferies Financial Group upgraded ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 price target for the company in a research report on Wednesday. KeyCorp raised their price target on ICU Medical from $198.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 13th. Needham & Company LLC restated a "hold" rating on shares of ICU Medical in a report on Wednesday, November 13th. Finally, StockNews.com raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, ICU Medical currently has an average rating of "Moderate Buy" and a consensus target price of $177.25.

ICU Medical Stock Performance

Shares of ICU Medical stock traded up $6.08 on Wednesday, reaching $166.19. 245,106 shares of the company were exchanged, compared to its average volume of 271,534. ICU Medical, Inc. has a 1-year low of $83.26 and a 1-year high of $196.26. The firm has a market cap of $4.07 billion, a price-to-earnings ratio of -35.03 and a beta of 0.62. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The company's 50-day moving average is $171.99 and its two-hundred day moving average is $150.34.

Insider Buying and Selling

In related news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the transaction, the chief executive officer now directly owns 104,593 shares of the company's stock, valued at $17,973,261.12. The trade was a 10.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David C. Greenberg sold 972 shares of ICU Medical stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total transaction of $153,682.92. Following the completion of the transaction, the director now directly owns 5,037 shares in the company, valued at $796,400.07. This represents a 16.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,364 shares of company stock valued at $6,869,878 in the last three months. 6.70% of the stock is currently owned by corporate insiders.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.